Mga Batayang Estadistika
| CIK | 892160 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Derma Sciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| February 2, 2018 |
DSCI / Derma Sciences, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 10, 2017 |
DSCI / Derma Sciences, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 7, 2017 |
15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-13070 DERMA SCIENCES, INC. (Exact name of registrant as specified |
|
| March 7, 2017 |
Financial Statements and Exhibits 8-K/A 1 d357019d8ka.htm FORM 8-K AMENDMENT NO. 2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 2 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or o |
|
| March 7, 2017 |
EX-2.1 2 d357019dex21.htm EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among DERMA SCIENCES, INC., DP MERGER SUB ONE, LLC, BIOD, LLC, And CYNTHIA WEATHERLY July 27, 2016 TABLE OF CONTENTS Page Article I THE MERGER 1 1.1 The Merger 1 1.2 Closing; Effective Time 2 1.3 Effect of the Merger 2 1.4 Certificate of Formation; Limited Liability Company Agreement 2 1.5 Managers and Officers 2 Arti |
|
| February 28, 2017 |
DSCI / Derma Sciences, Inc. / GARDNER LEWIS ASSET MANAGEMENT L P Activist Investment SC 13D/A 1 dsci022217.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Derma Sciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 249827502 (CUSIP Number) Gardner Lewis Asset Management, L.P. Attn: Len Sorgini, Chief Compliance Officer 285 Wilmington West Che |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
As filed with the Securities and Exchange Commission on February 24, 2017 Registration No. |
|
| February 24, 2017 |
EX-3.2 3 d354125dex32.htm EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF DERMA SCIENCES, INC., a Delaware corporation (the “Corporation”) ARTICLE I OFFICES Section 1. Registered Office. The registered office and registered agent of the Corporation in the State of Delaware shall be as set forth in the Certificate of Incorporation of the Corporation (the “Certificate of Incorporation”). Section 2 |
|
| February 24, 2017 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION DERMA SCIENCES, INC. ARTICLE FIRST: EX-3.1 2 d354125dex31.htm EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DERMA SCIENCES, INC. ARTICLE FIRST: The name of the corporation is Derma Sciences, Inc. (hereafter the “Corporation”). ARTICLE SECOND: The address of the Corporation’s registered office in the State of Delaware is 2711 Centerville Road, Suite 400, Wilmington, Delaware, 19808, County of New Castle. The |
|
| February 24, 2017 |
8-K 1 d354125d8k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 24, 2017 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS |
|
| February 23, 2017 |
SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $0.01 Series A Convertible Preferred Stock, par value $0.01 Series B Con |
|
| February 23, 2017 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 23, 2017 |
Integra LifeSciences Announces Acceptance of Shares Tendered into Offer for Derma Sciences, Inc. EX-99.(A)(1)(H) 2 d330748dex99a1h.htm EX-99.(A)(1)(H) Exhibit (a)(1)(H) Integra LifeSciences Announces Acceptance of Shares Tendered into Offer for Derma Sciences, Inc. Plainsboro, NJ – (GLOBE NEWSWIRE) – February 23, 2017 – Integra LifeSciences Holdings Corporation (“Integra”; NASDAQ:IART), a global leader in medical technology, announced today that its tender offer by its wholly-owned subsidiary |
|
| February 15, 2017 |
DSCI / Derma Sciences, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul |
|
| February 10, 2017 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2017 |
SC 14D9/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $0.01 Series A Convertible Preferred Stock, par value $0.01 Series B Con |
|
| February 8, 2017 |
DSCI / Derma Sciences, Inc. / FRANKLIN RESOURCES INC Passive Investment derm16a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 249827502 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DERMA SCIENCES, INC. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2016 (Date of Event Whic |
|
| February 6, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $0.01 Series A Convertible Preferred Stock, par value $0.01 Series B Convertible P |
|
| February 6, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. |
|
| January 25, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2017 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| January 25, 2017 |
Table of Contents SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $0.01 Series A Convertible Preferred Stock, par value $0.01 Series B Convertible P |
|
| January 25, 2017 |
214 Carnegie Center Suite 300 Princeton, New Jersey 08540 EX-99.(A)(1)(I) 2 d292797dex99a1i.htm EX-99.(A)(1)(I) Exhibit (a)(1)(I) 214 Carnegie Center Suite 300 Princeton, New Jersey 08540 January 25, 2017 To the Stockholders of Derma Sciences, Inc.: We are pleased to inform you that Derma Sciences, Inc. (the “Company”) has entered into a merger agreement providing for the acquisition of the Company by an indirect wholly owned subsidiary of Integra Lifesc |
|
| January 25, 2017 |
Integra LifeSciences Corporation 311 Enterprise Drive Plainsboro, NJ 08536 EX-99.(d)(3) Exhibit (d)(3) Integra LifeSciences Corporation 311 Enterprise Drive Plainsboro, NJ 08536 Derma Sciences, Inc. 214 Carnegie Center, Suite 300 Princeton, NJ 08540 Attention: Stephen T. Wills January 10, 2017 Ladies and Gentlemen: We refer to the Agreement and Plan of Merger, dated as of January 10, 2016 (the ?Merger Agreement?), among Derma Sciences, Inc. (?Derma?), Integra LifeScience |
|
| January 25, 2017 |
EX-99.(A)(1)(A) 2 d333140dex99a1a.htm EX-99.(A)(1)(A) Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock All Outstanding Shares of Series A Convertible Preferred Stock All Outstanding Shares of Series B Convertible Preferred Stock of Derma Sciences, Inc. at $7.00 Net Per Share of Common Stock, $32.00 Net Per Share of Series A Convertible Preferred |
|
| January 25, 2017 |
EX-99.(a)(1)(D) Exhibit (a) (1) (D) Offer To Purchase For Cash All Outstanding Shares of Common Stock, All Outstanding Shares of Series A Convertible Preferred Stock and All Outstanding Shares of Series B Convertible Preferred Stock of Derma Sciences, Inc. at $7.00 Net Per Share of Common Stock, $32.00 Net Per Share of Series A Convertible Preferred Stock and $48.00 Net Per Share of Series B Conve |
|
| January 25, 2017 |
EX-99.(D)(2) 8 d333140dex99d2.htm EX-99.(D)(2) Exhibit (d)(2) October 13, 2016 Integra LifeSciences Holdings Corporation 311 Enterprise Drive Plainsboro, NJ 08536 Attention: Peter Arduini Re: Confidentiality Agreement Ladies and Gentlemen: In connection with the consideration by Integra LifeSciences Holdings Corporation (“you”) of a possible negotiated transaction (a “Possible Transaction”) with D |
|
| January 25, 2017 |
EX-99.(d)(4) Exhibit (d)(4) CONFIDENTIAL January 9, 2017 Mr. Zubeen Shroff Galen Partners III, L.P. Galen Partners International III, L.P. Galen Employee Fund III, L.P. 680 Washington Boulevard 11th Floor Stamford, CT 06901 Re: Potential Merger Dear Zubeen: We are writing to Galen Partners III, L.P., Galen Partners International III, L.P. and Galen Employee Fund III, L.P. (collectively, the ?Galen |
|
| January 25, 2017 |
EX-99.(a)(1)(G) Exhibit (a)(1)(G) Integra LifeSciences Commences Previously Announced Cash Tender Offer to Acquire Derma Sciences, Inc. Plainsboro, NJ ? (GLOBE NEWSWIRE) ? January 25, 2017 ? Integra LifeSciences Holdings Corporation (?Integra?; NASDAQ:IART), a global leader in medical technology, announced today that its wholly-owned subsidiary, Integra Derma, Inc. (?Offeror?), is commencing a cas |
|
| January 25, 2017 |
EX-99.(a)(1)(B) Exhibit (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock, Series A Convertible Preferred Stock and Series B Convertible Preferred Stock of Derma Sciences, Inc. a Delaware corporation at $7.00 Net Per Share of Common Stock, $32.00 Net Per Share of Series A Convertible Preferred Stock and $48.00 Net Per Share of Series B Convertible Preferred Stock by Integra Derma, I |
|
| January 25, 2017 |
EX-99.(A)(1)(E) 6 d333140dex99a1e.htm EX-99.(A)(1)(E) Exhibit (a)(1)(E) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated as of January 25, 2017, and the related Letter o |
|
| January 25, 2017 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DERMA SCIENCES, INC. |
|
| January 25, 2017 |
EX-99.(a)(1)(C) Exhibit (a) (1) (C) Offer To Purchase For Cash All Outstanding Shares of Common Stock, All Outstanding Shares of Series A Convertible Preferred Stock and All Outstanding Shares of Series B Convertible Preferred Stock of Derma Sciences, Inc. at $7.00 Net Per Share of Common Stock, $32.00 Net Per Share of Series A Convertible Preferred Stock and $48.00 Net Per Share of Series B Conve |
|
| January 24, 2017 |
DSCI / Derma Sciences, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 23, 2017 |
DSCI / Derma Sciences, Inc. / GARDNER LEWIS ASSET MANAGEMENT L P Activist Investment SC 13D 1 dsci011117.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Derma Sciences, Inc. (Name of Issuer) Common Stock, $ 0.01 par value (Title of Class of Securities) 249827502 (CUSIP Number) Gardner Lewis Asset Management, L.P. Attn: Len Sorgini, Chief Compliance Officer 285 Wilmington West Chest |
|
| January 17, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $.01 per share (Title of Class of Securities) 249827205 (CUSIP Number of Class of S |
|
| January 17, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2017 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| January 17, 2017 |
Derma Sciences Buys MEDIHONEY® Brand From Long-Term Partner Secures 10-year Supply Source Exhibit 99.1 Derma Sciences Buys MEDIHONEY? Brand From Long-Term Partner Secures 10-year Supply Source PRINCETON, N.J. (January 11, 2017) ? Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, today announced that it has purchased the MEDIHONEY? brand and related intellectual property and goodwill from its long-term partner, New Zealand-based |
|
| January 17, 2017 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2017 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| January 13, 2017 |
DSCI / Derma Sciences, Inc. / Broadfin Capital, LLC Activist Investment SC 13D/A 1 d739183413d-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) Broadfin Capital, LLC 300 Park Avenue, 25th Floor New York, New York 10022 Telephone - (212) 808-24 |
|
| January 12, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $.01 per share (Title of Class of Securities) 249827205 (CUSIP Number of Class of S |
|
| January 12, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $.01 per share (Title of Class of Securities) 249827205 (CUSIP Number of Class of S |
|
| January 12, 2017 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2017 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or other jurisdiction of incor |
|
| January 12, 2017 |
Integra LifeSciences Holdings Corp. EX-99.1 Exhibit 99.1 11-Jan-2017 Integra LifeSciences Holdings Corp. (IART) Acquisition of Derma Sciences, Inc. by Integra LifeSciences Holdings Corporation Call Total Pages: 15 1-877-FACTSET www.callstreet.com Copyright ? 2001-2017 FactSet CallStreet, LLC Integra LifeSciences Holdings Corp. (IART) Acquisition of Derma Sciences, Inc. by Integra LifeSciences Holdings Corporation Call 11-Jan-2017 CO |
|
| January 11, 2017 |
EX-2.1 Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among INTEGRA LIFESCIENCES HOLDINGS CORPORATION, INTEGRA DERMA, INC. and DERMA SCIENCES, INC. Dated as of January 10, 2017 TABLE OF CONTENTS Page ARTICLE 1 THE OFFER AND THE MERGER 2 1.1 The Offer 2 1.2 Company Actions 5 1.3 The Merger 6 1.4 Closing and Effective Time of the Merger 7 ARTICLE 2 CONVERSION OF SECURITIES IN THE |
|
| January 11, 2017 |
SC TO-C 1 d316863d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2017 INTEGRA LIFESCIENCES HOLDINGS CORPORATION (Exact name of Registrant as specified in its charter) Delaware 0-26224 51-0317849 (State or ot |
|
| January 11, 2017 |
Integra LifeSciences Acquisition of Derma Sciences January 11, 2017 Ex99.2 EX-99.2 Integra LifeSciences Acquisition of Derma Sciences January 11, 2017 Ex99.2 Safe Harbor / Non-GAAP Financial Measures This presentation contains ?forward-looking statements?, including statements regarding the proposed transaction and the ability to consummate the proposed transaction. Statements in this document may contain, in addition to historical information, certain forward-looking st |
|
| January 11, 2017 |
EX-99.1 Exhibit 99.1 Integra LifeSciences to Acquire Derma Sciences Inc. and Announces Preliminary Fourth Quarter and Full Year 2016 Financial Results and 2017 Outlook ? Expands regenerative technology capabilities and accelerates advanced wound care strategy with the addition of amniotic tissue-based products ? Leverages existing sales channel with the addition of a complementary line of advanced |
|
| January 11, 2017 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) DERMA SCIENCES, INC. (Name of Subject Company) DERMA SCIENCES, INC. (Name of Persons Filing Statement) Common Stock, par value $.01 per share (Title of Class of Securities) 249827205 (CUSIP Number of Class of S |
|
| November 9, 2016 |
Derma Sciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| October 21, 2016 |
DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Exhibit 99.4 DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS Overview 1 Unaudited Pro Forma Consolidated Balance Sheet as of June 30, 2016 3 Unaudited Pro Forma Consolidated Statement of Operations for the Six Months Ended June 30, 2016 4 Unaudited Pro Forma Consolidated Statement of Operations for the Year Ended December 31, 2015 5 Notes to the Unaudited Pro Forma Conso |
|
| October 21, 2016 |
Exhibit 99.3 UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS OF BIOD, LLC AND SUBSIDIARIES FOR THE SIX MONTHS ENDED JUNE 30, 2016 AND 2015 Unaudited Consolidated Balance Sheet 1 Unaudited Consolidated Statements of Operations and Changes in Members? Equity 2 Unaudited Consolidated Statements of Cash Flows 3 Notes to Unaudited Interim Consolidated Financial Statements 4 BioD, LLC and Subsidiari |
|
| October 21, 2016 |
Financial Statements and Exhibits 8-K/A 1 v4508158ka.htm 8-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (C |
|
| October 21, 2016 |
EX-99.2 3 v450815ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 BioD, LLC and Subsidiaries Consolidated Financial Statements Fiscal Years Ended December 31, 2015 and 2014 The report accompanying these financial statements was issued by BDO USA, LLP, a Delaware limited liability partnership and the U.S. member of BDO International Limited, a UK company limited by guarantee. BioD, LLC and Subsidiaries Consoli |
|
| September 8, 2016 |
DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS EX-99.2 4 v448408ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS On September 1, 2016, Derma Sciences, Inc. (the “Company”) completed the previously announced sale of substantially all of the assets of its First Aid Products division (“FAD”) to Dukal Corporation (“Dukal”) for approximately $9.7 million in cash plus a promissory note i |
|
| September 8, 2016 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 v4484088k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) September 1, 2016 DERMA SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction of (Comm |
|
| September 8, 2016 |
Exhibit 2.1 ASSET PURCHASE AGREEMENT Dated as of July 26, 2016 By and among DERMA SCIENCES, INC. and DErMA FIRST AID PRODUCTS INC. and DUKAL CORPORATION CONFIDENTIAL TABLE OF CONTENTS Page SECTION 1. DEFINITIONS 1 1.1 Definitions 1 SECTION 2. SALE AND PURCHASE 3 2.1 Purchased Assets 3 2.2 Excluded Assets 4 2.3 Liabilities 4 SECTION 3. PURCHASE PRICE 5 3.1 Purchase Price 5 SECTION 4. CLOSING 5 SECT |
|
| September 8, 2016 |
DERMA SCIENCES COMPLETES THE SALE OF ITS FIRST AID PRODUCTS DIVISION EX-99.1 3 v448408ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DERMA SCIENCES COMPLETES THE SALE OF ITS FIRST AID PRODUCTS DIVISION PRINCETON, N.J. (September 1, 2016) – Derma Sciences, Inc. (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces the completion of the sale of its First Aid Division (FAD) to Dukal Corporation for $12.4 million, including inventory. T |
|
| August 26, 2016 |
Derma Sciences FORM 8-K (Current Report/Significant Event) ? SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fi |
|
| August 26, 2016 |
Derma Sciences FORM 8-K (Current Report/Significant Event) ? SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 25, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fi |
|
| August 11, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) File |
|
| August 11, 2016 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT by and among DERMA SCIENCES, INC. and THE PARTIES LISTED ON SCHEDULE 1 HERETO Dated as of July 27, 2016 CONFIDENTIAL Stock Purchase Agreement This Stock Purchase Agreement (this ?Agreement?) is made and entered into as of July 27, 2016, by and among Derma Sciences, Inc., a corporation organized under the laws of the state of Delaware (the ?Company?), and the I |
|
| August 11, 2016 |
EX-2.1 2 v446334ex2-1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among Derma Sciences, Inc., DP Merger Sub One, LLC, BioD, LLC, And Cynthia Weatherly July 27, 2016 **** This material has been omitted pursuant to a request for confidential treatment and filed separately with the Securities and Exchange Commission. CONFIDENTIAL TABLE OF CONTENTS Page Article I The Merger 1 1.1 T |
|
| August 8, 2016 |
Derma Sciences FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| July 29, 2016 |
Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this ?Agreement?) is made and entered into as of July 31, 2016 (the ?Separation Date?), by and between Barry Wolfenson (the ?Executive?) and Derma Sciences, Inc. (the ?Company?). The Company and Executive are sometimes collectively referred to herein as the Parties and individually as a Party. As used in this Agreement, the term ?affilia |
|
| July 29, 2016 |
July 28, 2016 Acquisition of BioD & FAD Divestiture Exhibit 99.2 July 28, 2016 Acquisition of BioD & FAD Divestiture Forward-Looking Statement-Looking Statements Statements contained in this presentation that are not statements of historical fact may be deemed to be forward looking statements. Without limiting the generality of the foregoing, words such as ?may,? ?will,? ?expect,? believe, anticipate, intend, could, estimate or continue are intende |
|
| July 29, 2016 |
EX-99.1 3 v445493ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DERMA SCIENCES TO ACQUIRE BIOD, SOLIDIFY ITS LEADERSHIP POSITION IN ADVANCED WOUND CARE AND REGENERATIVE PRODUCTS · Immediately accretive transaction will bring four proprietary high-margin product families and revenue of $22 million for the trailing 12 months ended June 30, 2016 · Will add 235 independent sales representatives and seven direct |
|
| July 29, 2016 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 29, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) File N |
|
| June 3, 2016 |
Submission of Matters to a Vote of Security Holders 8-K 1 v4416868k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS emplo |
|
| May 10, 2016 |
Derma Sciences 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| April 20, 2016 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to 240. |
|
| April 20, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive |
|
| March 15, 2016 |
Derma Sciences FORM 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2015 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-31070 DERMA SCIENCES, INC. (Name of |
|
| March 15, 2016 |
EX-10.41 2 v432348ex10-41.htm EXHIBIT 10.41 Exhibit 10.41 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is made and entered into as of December 21, 2015 (the “Separation Date”), by and between Edward J. Quilty (the “Executive”) and Derma Sciences, Inc. (the “Company”). The Company and Executive are sometimes collectively referred to herein as the Parties and individually as a P |
|
| March 15, 2016 |
Subsidiaries of Derma Sciences, Inc. Exhibit 21.1 Subsidiaries of Derma Sciences, Inc. Legal Name Trade Name State/Province of Incorporation Derma First Aid Products, Inc. Derma First Aid Products, Inc. Pennsylvania, United States Derma Sciences Canada Inc. Derma Sciences Canada Inc. Ontario, Canada Sunshine Products, Inc. Sunshine Products, Inc. Missouri, United States Derma Sciences Europe, Ltd. Derma Sciences Europe, Ltd. England, |
|
| March 15, 2016 |
AMENDMENT NO. 1 TO PATENT AND TECHNOLOGY LICENSE AGREEMENT Exhibit 10.42 AMENDMENT NO. 1 TO PATENT AND TECHNOLOGY LICENSE AGREEMENT This Amendment No. 1 dated effective July 12, 2015 (the “Effective Date”)amends the Patent and Technology License Agreement (“Agreement”), effective as of the 12th day of July, 2012 by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW 4 Street, Gainesville, Florida 32601 and Derma Science |
|
| March 1, 2016 |
Derma Sciences FORM 8-K (Current Report/Significant Event) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2016 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fi |
|
| February 16, 2016 |
DSCI / Derma Sciences, Inc. / Baker Brothers Advisors LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2016 |
DSCI / Derma Sciences, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 11, 2016 |
SC 13G/A 1 dscia121116.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of th |
|
| February 10, 2016 |
DSCI / Derma Sciences, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| January 29, 2016 |
Exhibit 1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of January 29, 2016, is by and among RA Capital Management, LLC, Peter Kolchinsky, and RA Capital Healthcare Fund, L. |
|
| January 29, 2016 |
DSCI / Derma Sciences, Inc. / RA Capital Management, LLC - SC 13G Passive Investment SC 13G 1 v430156sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) January 20, 2016 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| January 8, 2016 |
DSCI / Derma Sciences, Inc. / FRANKLIN RESOURCES INC Passive Investment derm15in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 249827502 13G Page 1 of 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DERMA SCIENCES, INC. (Name of Issuer) Common Stock, $.01 par value (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2015 (Date of Event Which |
|
| December 21, 2015 |
EX-10.1 2 v427466ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SEPARATION AGREEMENT This Separation Agreement (this “Agreement”) is made and entered into as of December 21, 2015 (the “Separation Date”), by and between Edward J. Quilty (the “Executive”) and Derma Sciences, Inc. (the “Company”). The Company and Executive are sometimes collectively referred to herein as the Parties and individually as a Party |
|
| December 21, 2015 |
EX-99.1 3 v427466ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DERMA SCIENCES ANNOUNCES LEADERSHIP AND CEO TRANSITION CEO Edward J. Quilty to Depart the Company Lead Director Stephen T. Wills Named Interim Executive Chairman PRINCETON, N.J. (December 21, 2015) – Derma Sciences, Inc. (NASDAQ: DSCI), a tissue regeneration company focused on advanced wound and burn care, announces that Stephen T. Wills, the L |
|
| December 21, 2015 |
Derma Sciences FORM 8-K (Current Report/Significant Event) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2015 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fi |
|
| December 16, 2015 |
DSCI / Derma Sciences, Inc. / Broadfin Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) KEVIN KOTLER BROA |
|
| November 6, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 10-Q 1 v42276310q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission f |
|
| August 7, 2015 |
8-K 1 v4175448k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2015 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS emp |
|
| August 7, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 10-Q 1 v41625410q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| May 29, 2015 |
Derma Sciences 8-K (Current Report/Significant Event) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2015 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) File Nu |
|
| May 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2015 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| April 16, 2015 |
DSCI / Derma Sciences, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| April 9, 2015 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to 240. |
|
| April 9, 2015 |
Derma Sciences DEFINITIVE PROXY STATEMENT DEF 14A 1 v406710def14a.htm DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commissi |
|
| March 20, 2015 |
DSCI / Derma Sciences, Inc. / Broadfin Capital, LLC - AMENDMENT NO. 1 TO THE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) KEVIN KOTLER BROA |
|
| March 18, 2015 |
DSCI / Derma Sciences, Inc. / Broadfin Capital, LLC - SCHEDULE 13D Activist Investment SC 13D 1 sc13d1004200103172015.htm SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securit |
|
| March 18, 2015 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the shares of Common Stock, $0.01 par value per share, of Derma Sciences, Inc. This Joint Filing Agreement shall b |
|
| March 11, 2015 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.39 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Derma Sciences, Inc. (?Employer?), and Edward J. Quilty (?Employee?) are parties to an Employment Agreement dated March 7, 2012, as amended by First Amendment dated December 20, 2012 and by Second Amendment effective March 31, 2013 (the ?Agreement?). WHEREAS, Employer and Employee desire to amend the Agreement to extend the Term for a period of |
|
| March 11, 2015 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.41 4 v402490ex10-41.htm EXHIBIT 10.41 EXHIBIT 10.41 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Derma Sciences, Inc. (“Employer”), and Barry J. Wolfenson (“Employee”) are parties to an Employment Agreement dated March 8, 2012, as amended by First Amendment dated December 20, 2012 and by Second Amendment effective March 31, 2013 (the “Agreement”). WHEREAS, Employer and Employee desire to amend th |
|
| March 11, 2015 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.42 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Derma Sciences, Inc. (?Employer?), and Robert C. Cole (?Employee?) are parties to an Employment Agreement dated March 7, 2012, as amended by First Amendment dated December 20, 2012 and by Second Amendment effective March 31, 2013 (the ?Agreement?). WHEREAS, Employer and Employee desire to amend the Agreement to extend the Term for a period of t |
|
| March 11, 2015 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.40 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Derma Sciences, Inc. (?Employer?), and John E. Yetter (?Employee?) are parties to an Employment Agreement dated March 7, 2012, as amended by First Amendment dated December 20, 2012 and by Second Amendment effective March 31, 2013 (the ?Agreement?). WHEREAS, Employer and Employee desire to amend the Agreement to extend the Term for a period of t |
|
| March 11, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2014 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-31070 DERMA SCIENCES, INC. (Name of |
|
| March 11, 2015 |
EXHIBIT 10.44 EMPLOYMENT AGREEMENT THIS AGREEMENT, made effective the 9th day of March, 2015 by and between Derma Sciences, Inc., a business corporation organized under the laws of the State of Delaware (?Employer?), and John Caminis, M.D. (?Employee?). WHEREAS, Employee is to be employed by Derma Sciences as its Chief Medical Officer, NOW, THEREFORE, the parties hereto, in consideration of the mu |
|
| March 11, 2015 |
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.43 THIRD AMENDMENT TO EMPLOYMENT AGREEMENT Derma Sciences, Inc. (?Employer?), and Frederic Eigner (?Employee?) are parties to an Employment Agreement dated March 12, 2012, as amended by First Amendment dated December 20, 2012 and by Second Amendment effective March 31, 2013 (the ?Agreement?). WHEREAS, Employer and Employee desire to amend the Agreement to extend the Term for a period of |
|
| March 11, 2015 |
Subsidiaries of Derma Sciences, Inc. Exhibit 21.1 Subsidiaries of Derma Sciences, Inc. Legal Name Trade Name State/Province of Incorporation Derma First Aid Products, Inc. Derma First Aid Products, Inc. Pennsylvania, United States Derma Sciences Canada Inc. Derma Sciences Canada Inc. Ontario, Canada Sunshine Products, Inc. Sunshine Products, Inc. Missouri, United States Derma Sciences Europe, Ltd. Derma Sciences Europe, Ltd. England, |
|
| February 17, 2015 |
DSCI / Derma Sciences, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 17, 2015 |
SC 13G 1 dsci21315.htm CONSONANCE CAPITAL MANAGEMENT LP UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2014 (Date of Event which Requires Filing of this St |
|
| February 17, 2015 |
DSCI / Derma Sciences, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 17, 2015 |
DSCI / Derma Sciences, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| August 6, 2014 |
CERTIFICATE OF INCORPORATION DERMA SCIENCES, INC. (as amended on June 6, 2014) Exhibit 3.01 CERTIFICATE OF INCORPORATION OF DERMA SCIENCES, INC. (as amended on June 6, 2014) I, the undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the ? DGCL ?), certify as follows: Article I NAME The name of the corporation is Derma Sciences, Inc. (the ?Corpora |
|
| August 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q 10-Q 1 v38483310q.htm FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2014 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file n |
|
| July 18, 2014 |
DSCI / Derma Sciences, Inc. S-8 - - FORM S-8 As filed with the Securities and Exchange Commission on July 18, 2014 Registration No. |
|
| May 23, 2014 |
8-K 1 v3796278k.htm 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2014 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer o |
|
| May 23, 2014 |
Derma Sciences, Inc. 2014 Director Compensation Program Exhibit 10.1 Derma Sciences, Inc. 2014 Director Compensation Program The 2014 Director Compensation Program of Derma Sciences, Inc. (the “Company”), effective May 21, 2014, applies to the Company’s directors upon election or appointment to the Board of Directors of the Company (the “Board of Directors”). General Board of Directors Service - Equity · Upon election or appointment, outside directors |
|
| May 23, 2014 |
AMENDED AND RESTATED DERMA SCIENCES, INC. 2012 EQUITY INCENTIVE PLAN (as amended on May 20, 2014) Exhibit 10.2 AMENDED AND RESTATED DERMA SCIENCES, INC. 2012 EQUITY INCENTIVE PLAN (as amended on May 20, 2014) 1. Establishment, Purpose, Duration. a. Establishment. Derma Sciences, Inc. (the “Company”), hereby establishes an equity compensation plan to be known as the Derma Sciences, Inc. 2012 Equity Incentive Plan (the “Plan”). The Plan is effective as of May 30, 2012 (the “Effective Date”), sub |
|
| May 7, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2014 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| April 9, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive |
|
| April 9, 2014 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement x Definitive Additional Materials ¨ Soliciting Material Pursuant to 240. |
|
| March 27, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive |
|
| March 27, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 21, 2014 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) File |
|
| March 21, 2014 |
DSCI / Derma Sciences, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| March 13, 2014 |
CERTIFICATE OF INCORPORATION DERMA SCIENCES, INC. (as amended on May 29, 2013) Exhibit 3.01 CERTIFICATE OF INCORPORATION OF DERMA SCIENCES, INC. (as amended on May 29, 2013) I, the undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “ DGCL ”), certify as follows: Article I NAME The name of the corporation is Derma Sciences, Inc. (the “Corpora |
|
| March 13, 2014 |
Subsidiaries of Derma Sciences, Inc. Exhibit 21.1 Subsidiaries of Derma Sciences, Inc. Legal Name Trade Name State/Province of Incorporation Derma First Aid Products, Inc. Derma First Aid Products, Inc. Pennsylvania, United States Derma Sciences Canada Inc. Derma Sciences Canada Inc. Ontario, Canada Sunshine Products, Inc. Sunshine Products, Inc. Missouri, United States Derma Sciences Europe, Ltd. Derma Sciences Europe, Ltd. England, |
|
| March 13, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2013 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-31070 DERMA SCIENCES, INC. (Name of |
|
| March 13, 2014 |
LICENSE, MARKET DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 10.38 LICENSE, MARKET DEVELOPMENT AND COMMERCIALIZATION AGREEMENT This License, MARKET DEVELOPMENT AND COMMERCIALIZATION Agreement (the “Agreement”) is entered into as of January 14, 2014 (the “Effective Date”) by and between BioDLogics, LLC, a Delaware limited liability company having a principal place of business at 1715 Aaron Brenner Drive, Suite 204, Memphis, TN 38120 (“BIOD”), and Der |
|
| February 14, 2014 |
DSCI / Derma Sciences, Inc. / 12 West Capital Management LP - DERMA13GAM2DEC13 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* DERMA SCIENCES, INC. (Name of Issuer) CLASS COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2014 |
DSCI / Derma Sciences, Inc. / Raging Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827 50 2 (CUSIP Number) Dec |
|
| February 14, 2014 |
DSCI / Derma Sciences, Inc. / RA Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 11, 2014 |
DSCI / Derma Sciences, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 10, 2014 |
DSCI / Derma Sciences, Inc. / BAKER FELIX - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 27, 2014 |
Filed pursuant to Rule 424(b)(2) Registration File Nos. 333-192945 and 333-193530 PROSPECTUS SUPPLEMENT (To Prospectus dated January 6, 2014) 6,521,739 Shares DERMA SCIENCES, INC. Common Stock $11.50 per share • Derma Sciences, Inc. is offering 6,521,739 shares of common stock. • The last reported sale price of our common stock on January 23, 2014, was $11.99 per share. • Trading symbol: NASDAQ Ca |
|
| January 27, 2014 |
Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock EX-99.2 5 v366351ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock PRINCETON, N.J. (January 24, 2014) – Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI), a tissue regeneration company focused on advanced wound care, today announced the pricing of an underwritten public offering of 6,521,739 shares of common stock at a price to |
|
| January 27, 2014 |
DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK EX-99.1 4 v366351ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK PRINCETON, N.J. (January 23, 2014) – Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that it intends to offer shares of its common stock in a public offering. The offering is subject to market |
|
| January 27, 2014 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3663518k.htm 8-K CURRENT REPORT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 24, 2014 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commiss |
|
| January 27, 2014 |
6,521,739 Shares DERMA SCIENCES, INC. Common Stock PURCHASE AGREEMENT EX-1.1 2 v366351ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 EXECUTION COPY 6,521,739 Shares DERMA SCIENCES, INC. Common Stock PURCHASE AGREEMENT January 24, 2014 Piper Jaffray & Co. Canaccord Genuity Inc. As Representatives of the Several Underwriters named in Schedule I hereto c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Derma Sciences, In |
|
| January 24, 2014 |
As filed with the Securities and Exchange Commission on January 24, 2014. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DERMA SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 23-2328753 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. |
|
| January 23, 2014 |
The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| January 21, 2014 |
EX-99.1 2 v365842ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Derma Sciences Announces Record Revenues for the 2013 Fourth Quarter and Full Year, Introduces 2014 Revenue Guidance, Provides Update on DSC127 Phase 3 Clinical Trials Expects 2014 total revenue of $92 million, up 15.5% over 2013, organic advanced wound care revenue growth of 30% to 40% DSC127 clinical trial sites to be initiated in South Afric |
|
| January 21, 2014 |
Regulation FD Disclosure, Financial Statements and Exhibits 8-K 1 v3658428k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 16, 2014 DERMA SCIENCES, INC. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (I |
|
| January 17, 2014 |
Exhibit 99.1 Derma Sciences Enters the Skin Substitute Market with Licensing Agreement for Innovative Amniotic Membrane Wound Care Products Commercial launch into this $500 million market, along with its drug candidate for the treatment of diabetic foot ulcers, underscores company’s commitment to regenerative medicine PRINCETON, N.J.-(BUSINESS WIRE)-Jan. 14, 2014- Derma Sciences, Inc. (Nasdaq:DSCI |
|
| January 17, 2014 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 14, 2014 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) |
|
| January 9, 2014 |
Derma Sciences, Inc. Common Stock Filed Pursuant to 424(b)(3) Registration File No. 333-192945 PROSPECTUS $75,000,000 Derma Sciences, Inc. Common Stock Warrants Units From time to time, we may offer any combination of the securities described in this prospectus, either individually or in units. We may also offer common stock upon the exercise of warrants. Such securities may be offered and sold by us in one or more offerings with |
|
| December 20, 2013 |
DSCI / Derma Sciences, Inc. / Broadfin Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 19, 2013 |
S-3 1 v363301s3.htm FORM S-3 As filed with the Securities and Exchange Commission on December 19, 2013 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-3 REGISTRATION STATEMENT Under THE SECURITIES ACT OF 1933 DERMA SCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 23-2328753 (State or other jurisdiction of incorporation or organiz |
|
| December 13, 2013 |
As filed with the Securities and Exchange Commission on December 13, 2013 Registration No. |
|
| November 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| November 12, 2013 |
Exhibit 10.1 SUBSCRIPTION AGREEMENT between COMVITA LIMITED and DERMA SCIENCES INC SHARP TUDHOPE TAURANGA Table of Contents 1. Definitions And Construction 1 2. Agreement To Subscribe 3 3. Further Shares 3 4. Settlement 4 5. Appointment of Director 4 6. Default By Investor 5 7. Notices 5 8. Miscellaneous Clauses 7 Subscription Agreement Date: 3rd September, 2013 Parties 1. DERMA SCIENCES INC (?the |
|
| September 5, 2013 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits 8-K 1 v3544048k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2013 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS |
|
| September 5, 2013 |
DERMA SCIENCES ACQUIRES 7.3% OF COMVITA TO SUPPORT VERTICAL INTEGRATION OF KEY COMPONENT IN MEDIHONEY® PRODUCTS Edward J. Quilty joins Comvita board of directors PRINCETON, N.J. (September 4, 2013) – Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced a $7.0 million strategic investment in Comvita Limited (NZX: CVT), a gl |
|
| August 12, 2013 |
Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 v3526108k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 12, 2013 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS em |
|
| August 12, 2013 |
DSCI / Derma Sciences, Inc. / BAKER FELIX - SC 13G/A Passive Investment SC 13G/A 1 v352602sc13ga.htm SC 13G/A SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. 2)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) July 24, 2013 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| August 12, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2013 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| August 12, 2013 |
EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Derma Sciences, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. August 12, 2013 BAKER BROS. ADVISORS LP By: Baker Bros. Advisors (GP) LLC, its gen |
|
| August 12, 2013 |
Exhibit 99.1 DERMA SCIENCES REPORTS SECOND QUARTER FINANCIAL RESULTS ADVANCED WOUND CARE SALES UP 36%, NOW REPRESENT 44% OF NET SALES Conference call begins at 11:00 a.m. Eastern time today PRINCETON, N.J. (August 12, 2013) – Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three |
|
| May 30, 2013 |
DSCI / Derma Sciences, Inc. / Raging Capital Management, LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827 50 2 (CUSIP Number) May |
|
| May 30, 2013 |
EX-99.1 2 ex991to13g0773801305282013.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated May 30, 2013 (including amendments thereto) with respect to the Common Stock of Derma Scien |
|
| May 24, 2013 |
Derma Sciences, Inc. 2013 Director Compensation Program Exhibit 10.1 Derma Sciences, Inc. 2013 Director Compensation Program The 2013 Director Compensation Program of Derma Sciences, Inc. (the “Company”), effective May 23, 2013, applies to the Company’s directors upon election or appointment to the Board of Directors of the Company (the “Board of Directors”). General Board of Directors Service - Equity · Upon election or appointment, outside directors |
|
| May 24, 2013 |
AMENDED AND RESTATED DERMA SCIENCES, INC. 2012 EQUITY INCENTIVE PLAN (as amended on May 22, 2013) Exhibit 10.2 AMENDED AND RESTATED DERMA SCIENCES, INC. 2012 EQUITY INCENTIVE PLAN (as amended on May 22, 2013) 1. Establishment, Purpose, Duration. a. Establishment. Derma Sciences, Inc. (the “Company”), hereby establishes an equity compensation plan to be known as the Derma Sciences, Inc. 2012 Equity Incentive Plan (the “Plan”). The Plan is effective as of May 30, 2012 (the “Effective Date”), sub |
|
| May 24, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2013 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| May 15, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2013 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| May 1, 2013 |
DSCI / Derma Sciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - FORM SC 13G/A Passive Investment SC 13G/A 1 v343477sc13ga.htm FORM SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) April 26, 2013 (Date of Event Which Requires Filing of this Statement) Check t |
|
| April 12, 2013 |
- DEFINITIVE ADDITIONAL MATERIALS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to 240. |
|
| April 12, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to 240. |
|
| April 1, 2013 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to 240. |
|
| April 1, 2013 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2013 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) File |
|
| March 28, 2013 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.12 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (?Employer?) and John E. Yetter (?Employee?) are parties to that certain Employment Agreement dated as of March 7, 2012, as amended on December 20, 2012 (the ?Agreement?). WHEREAS, Employer and Employee desire to amend the Agreement to extend the term for two years and add a requirement for Employee to sign a rele |
|
| March 28, 2013 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.15 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (?Derma U.S?), Derma Sciences Canada, Inc. (?Derma Canada?) and Frederic Eigner (?Employee?) are parties to that certain Employment Agreement dated as of March 12, 2012, as amended on December 20, 2012 (the ?Agreement?). WHEREAS, Derma U.S., Derma Canada and Employee desire to amend the Agreement to extend the ter |
|
| March 28, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K S Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2012 ¨ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-31070 DERMA SCIENCES, INC. (Name of |
|
| March 28, 2013 |
Subsidiaries of Derma Sciences, Inc. Exhibit 21.1 Subsidiaries of Derma Sciences, Inc. Legal Name Trade Name State/Province of Incorporation Derma First Aid Products, Inc. Derma First Aid Products, Inc. Pennsylvania, United States Derma Sciences Canada Inc. Derma Sciences Canada Inc. Ontario, Canada Sunshine Products, Inc. Sunshine Products, Inc. Missouri, United States Derma Sciences Europe, Ltd. Derma Sciences Europe, Ltd. England, |
|
| March 28, 2013 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.11 2 v336761ex10-11.htm EXHIBIT 10.11 Exhibit 10.11 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and Edward J. Quilty (“Employee”) are parties to that certain Employment Agreement dated as of March 7, 2012, as amended on December 20, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to extend the term for two years and |
|
| March 28, 2013 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.14 5 v336761ex10-14.htm EXHIBIT 10.14 Exhibit 10.14 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and Robert C. Cole (“Employee”) are parties to that certain Employment Agreement dated as of March 7, 2012, as amended on December 20, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to extend the term for two years and a |
|
| March 28, 2013 |
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT EX-10.13 4 v336761ex10-13.htm EXHIBIT 10.13 Exhibit 10.13 SECOND AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and Barry Wolfenson (“Employee”) are parties to that certain Employment Agreement dated as of March 8, 2012, as amended on December 20, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to extend the term for two years and |
|
| February 14, 2013 |
DSCI / Derma Sciences, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 14, 2013 |
DSCI / Derma Sciences, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 14, 2013 |
DSCI / Derma Sciences, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 derm.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: DERMA SCIENCES, INC. Title of Class of Securities: Common Stock CUSIP Number: 249827502 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a |
|
| February 14, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 249827502 (CUSIP Number) Dece |
|
| February 1, 2013 |
DSCI / Derma Sciences, Inc. / BAKER BROS. ADVISORS LP - SC 13G/A Passive Investment SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 3, 2013 |
Exhibit 991. Joint Filing Agreement In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $.01 per share, of Derma Sciences, Inc. This Joint Filing Agreement shall be filed as |
|
| January 3, 2013 |
Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints Frederick C. Wasch signing singly, the undersigned’s true and lawful attorney-in-fact to: 1. Execute for and on behalf of the undersigned all documents relating to the business of Raging Capital Management, LLC including, but not limited to, all filings with the Securities and Exchange C |
|
| January 3, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Derma Sciences, Inc. (Name of Issuer) Common Stock, par value $.01 per share (Title of Class of Securities) 249827 50 2 (CUSIP Number) STEVE WOLOSKY, E |
|
| December 21, 2012 |
2012 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED SHARE UNIT AGREEMENT (Executive Officer) EXHIBIT 10.2 2012 EQUITY INCENTIVE PLAN PERFORMANCE-BASED RESTRICTED SHARE UNIT AGREEMENT (Executive Officer) THIS PERFORMANCE-BASED RESTRICTED SHARE UNIT AGREEMENT (this “Agreement”), hereby made between Derma Sciences, Inc., a Delaware corporation (the “Company”) and the individual named below (the “Awardee”) evidences a Restricted Share Unit award, pursuant to the Derma Sciences, Inc. 2012 Equi |
|
| December 21, 2012 |
AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.6 AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and Robert C. Cole (“Employee”) are parties to that certain Employment Agreement dated as of March 7, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to remove Employee’s ability to receive severance benefits upon Employee’s voluntary termination of employment within six m |
|
| December 21, 2012 |
AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.4 AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and John E. Yetter (“Employee”) are parties to that certain Employment Agreement dated as of March 7, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to remove Employee’s ability to receive severance benefits upon Employee’s voluntary termination of employment within six m |
|
| December 21, 2012 |
AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.7 AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Derma U.S.”), Derma Sciences Canada, Inc. (“Derma Canada”) and Frederic Eigner (“Employee”) are parties to that certain Employment Agreement dated as of March 12, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to remove Employee’s ability to receive severance benefits upon Employee’ |
|
| December 21, 2012 |
8-K 1 v3307738k.htm FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 20, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS |
|
| December 21, 2012 |
2012 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT AGREEMENT (Executive Officer) EXHIBIT 10.1 2012 EQUITY INCENTIVE PLAN RESTRICTED SHARE UNIT AGREEMENT (Executive Officer) THIS RESTRICTED SHARE UNIT AGREEMENT (this “Agreement”), hereby made between Derma Sciences, Inc., a Delaware corporation (the “Company”) and the individual named below (the “Awardee”) evidences a Restricted Share Unit award, pursuant to the Derma Sciences, Inc. 2012 Equity Incentive Plan (the “Plan”), and |
|
| December 21, 2012 |
AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.3 AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and Edward J. Quilty (“Employee”) are parties to that certain Employment Agreement dated as of March 7, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to remove Employee’s ability to receive severance benefits upon Employee’s voluntary termination of employment within six |
|
| December 21, 2012 |
AMENDMENT TO EMPLOYMENT AGREEMENT EXHIBIT 10.5 AMENDMENT TO EMPLOYMENT AGREEMENT WHEREAS, Derma Sciences, Inc. (“Employer”) and Barry Wolfenson (“Employee”) are parties to that certain Employment Agreement dated as of March 8, 2012 (the “Agreement”). WHEREAS, Employer and Employee desire to amend the Agreement to remove Employee’s ability to receive severance benefits upon Employee’s voluntary termination of employment within six |
|
| December 10, 2012 |
3,062,000 Shares1 DERMA SCIENCES, INC. Common Stock PURCHASE AGREEMENT EXECUTION COPY 3,062,000 Shares1 DERMA SCIENCES, INC. Common Stock PURCHASE AGREEMENT December 6, 2012 Piper Jaffray & Co. As Representative of the Several Underwriters named in Schedule I hereto U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Derma Sciences, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Un |
|
| December 10, 2012 |
Financial Statements and Exhibits - FORM 8-K/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of |
|
| December 7, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| December 7, 2012 |
Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock EX-99.2 4 v329968ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Derma Sciences Announces Pricing of UNDERWRITTEN PUBLIC Offering of Common Stock PRINCETON, N.J. (December 6, 2012) – Derma Sciences, Inc. (the “Company”)(Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of an underwritten public offering of 3,062,000 shares of common stock a |
|
| December 7, 2012 |
DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 DERMA SCIENCES ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK PRINCETON, N.J. (December 5, 2012) – Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that it intends to offer shares of its common stock in a public offering. The offering is subject to market and other conditions, and there can be n |
|
| December 7, 2012 |
Filed pursuant to Rule 424(b)(2) Registration File No. 333-173870 and 333-185298 PROSPECTUS SUPPLEMENT (To Prospectus dated May 20, 2011) 3,062,000 Shares DERMA SCIENCES, INC. Common Stock $10.34 per share • Derma Sciences, Inc. is offering 3,062,000 shares of common stock • The last reported sale price of our common stock on December 5, 2012, was $10.34 per share • Trading symbol: NASDAQ Capital |
|
| December 6, 2012 |
S-3MEF 1 v329786s3mef.htm S-3MEF As filed with the Securities and Exchange Commission on December 6, 2012. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 DERMA SCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter) DELAWARE 23-2328753 (State or Other Jurisdiction of Incorp |
|
| December 5, 2012 |
The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. |
|
| November 9, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2012 ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| September 20, 2012 |
CERTIFICATE OF INCORPORATION DERMA SCIENCES, INC. Exhibit 3.1 CERTIFICATE OF INCORPORATION OF DERMA SCIENCES, INC. I, the undersigned, for the purpose of creating and organizing a corporation under the provisions of and subject to the requirements of the General Corporation Law of the State of Delaware (the “DGCL”), certify as follows: Article I Name The name of the corporation is Derma Sciences, Inc. (the “Corporation”). Article II Registered Of |
|
| September 20, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporatio |
|
| September 20, 2012 |
DERMA SCIENCES, INC. Article I Exhibit 3.2 BY-LAWS OF DERMA SCIENCES, INC. Article I Offices Section 1.01 Offices. The address of the registered office of Derma Sciences, Inc. (hereinafter called the “Corporation”) in the State of Delaware shall be at 901 N. Market Street, Suite 705, Wilmington, County of New Castle, Delaware 19801. The Corporation may have other offices, both within and without the State of Delaware, as the bo |
|
| September 20, 2012 |
DERMA SCIENCES, INC. (a Pennsylvania Corporation) DERMA SCIENCES, INC. (a Delaware Corporation) Exhibit 2.1 DERMA SCIENCES, INC. (a Pennsylvania Corporation) AND DERMA SCIENCES, INC. (a Delaware Corporation) This Agreement and Plan of Merger (this “Agreement”) is dated September 5, 2012 by and between Derma Sciences, Inc., a Pennsylvania corporation (“Derma Pennsylvania”) and Derma Sciences, Inc., a Delaware corporation (“Derma Delaware”). Recitals A. Derma Pennsylvania is a corporation duly |
|
| August 30, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. 1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q/A (Amendment No. |
|
| August 13, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| August 13, 2012 |
PATENT AND TECHNOLOGY LICENSE AGREEMENT Exhibit 10.1 PATENT AND TECHNOLOGY LICENSE AGREEMENT This Patent and Technology License Agreement (“Agreement”), effective as of the 12th day of July, 2012 (the “Effective Date”), is by and between Quick-Med Technologies, Inc., a Nevada corporation having offices at 902 NW 4 Street, Gainesville, Florida 32601 (“QMT”) and Derma Sciences, Inc., a Pennsylvania corporation having offices at 214 Carneg |
|
| July 18, 2012 |
Entry into a Material Definitive Agreement - FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 12, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fi |
|
| July 3, 2012 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 2, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| July 2, 2012 |
424B3 1 v317567424b3.htm FORM 424(B)(3) Rule 424(b)(3) Registration No. 333-148332 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED JANUARY 2, 2008 OF DERMA SCIENCES, INC. RELATING TO RESALES BY SELLING SHAREHOLDERS OF SHARES OF COMMON STOCK This Prospectus Supplement supplements the Prospectus included in Form S-3 (No. 333-148332), as amended, dated January 2, 2008 (the “Prospectus”). This Prospec |
|
| July 2, 2012 |
Rule 424(b)(3) Registration No. 333-151028 PROSPECTUS SUPPLEMENT NO. 1 TO PROSPECTUS DATED JULY 27, 2010 OF DERMA SCIENCES, INC. RELATING TO RESALES BY SELLING SHAREHOLDERS OF SHARES OF COMMON STOCK This Prospectus Supplement supplements the Prospectus included in Form S-3 (No. 333-151028), as amended, dated July 27, 2010 (the “Prospectus”). This Prospectus Supplement should be read in conjunction |
|
| June 29, 2012 |
Financial Statements and Exhibits - AMENDMENT NO.1 TO FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer o |
|
| June 29, 2012 |
EX-99.2 3 v316591ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MEDEFFICIENCY, INC. FINANCIAL STATEMENTS YEAR ENDED DECEMBER 31, 2011 MEDEFFICIENCY, INC. YEAR ENDED DECEMBER 31, 2011 CONTENTS Page Independent auditors’ report 1 Financial statements: Balance sheet 2 Statement of income 4 Statement of shareholders’ equity 5 Statement of cash flows 6 Notes to financial statements 7 GHP Horwath, P.C. Member Cro |
|
| June 29, 2012 |
Exhibit 99.4 DERMA SCIENCES, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Overview 1 Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2012 3 Unaudited Pro Forma Condensed Consolidated Statement of Operations for the Three Months Ended March 31, 2012 4 Unaudited Pro Forma Condensed Consolidated Statement of Operations for the Year Ended December |
|
| June 29, 2012 |
Exhibit 99.3 UNAUDITED INTERIM FINANCIAL STATEMENTS OF MEDEFFICIENCY, INC. FOR THE THREE MONTHS ENDED MARCH 31, 2012 AND 2011 Page Unaudited Balance Sheets 1 Unaudited Statements of Operations 2 Unaudited Statements of Cash Flows 3 Notes to Unaudited Interim Financial Statements 4 Medefficiency, Inc. Balance Sheets (Unaudited) March 31, 2012 December 31, 2011 ASSETS Current Assets Cash and equival |
|
| June 5, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| June 5, 2012 |
DERMA SCIENCES, INC. 2012 EQUITY INCENTIVE PLAN Exhibit 10.1 DERMA SCIENCES, INC. 2012 EQUITY INCENTIVE PLAN 1. Establishment, Purpose, Duration. a. Establishment .. Derma Sciences, Inc. (the “Company”), hereby establishes an equity compensation plan to be known as the Derma Sciences, Inc. 2012 Equity Incentive Plan (the “Plan”). The Plan is effective as of May 30, 2012 (the “Effective Date”), subject to the approval of the Plan by the stockhol |
|
| May 29, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* DERMA SCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 249827502 (CUSIP Number) May 17, 2012 (Date |
|
| May 18, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fil |
|
| May 14, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 1-31070 Derma Sciences, Inc. |
|
| May 4, 2012 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 1, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) File |
|
| May 4, 2012 |
Derma Sciences, Inc. 2012 Director Compensation Program Exhibit 10.1 Derma Sciences, Inc. 2012 Director Compensation Program The 2012 Director Compensation Program of Derma Sciences, Inc. (the “Company”), effective May 1, 2012, applies to the Company’s directors upon election or appointment to the Board of Directors of the Company (the “Board of Directors”). General Board of Directors Service - Equity · Upon election or appointment, outside directors r |
|
| April 20, 2012 |
EX-99.1 2 v309925ex99-1.htm Derma Sciences Completes MedEfficiency Acquisition - Assumes Direct Sales For TCC-EZ™, the High-Growth, Market-Leading, Gold-Standard Treatment for Diabetic Foot Ulcers - PRINCETON, N.J. (April 17, 2012) – Derma Sciences, Inc. (Nasdaq: DSCI)(“Derma Sciences”), a medical device and pharmaceutical company focused on advanced wound care, has completed its previously announ |
|
| April 20, 2012 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets - SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 16, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) F |
|
| April 17, 2012 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement x Definitive Additional Materials o Soliciting Material Pursuant to 240. |
|
| April 17, 2012 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to 240. |
|
| April 11, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: February 28, 2009 Estimated average burden hours per response… 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.) DERMA SCIENCES, INC. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 249827502 (CUSIP Number) April 2, 2012 (Date o |
|
| April 6, 2012 |
SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to 240. |
|
| April 5, 2012 |
DSCI / Derma Sciences, Inc. / 12 West Capital Management LP - DERMA13GAPR12 Passive Investment SC 13G 1 derma13gapr12.htm DERMA13GAPR12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* DERMA SCIENCES, INC. (Name of Issuer) CLASS COMMON STOCK, $0.01 PAR VALUE PER SHARE (Title of Class of Securities) 249827502 (CUSIP Number) March 27, 2012 (Date of Event Which Requires Filing of this Statement) Che |
|
| April 4, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 2, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) Fi |
|
| April 4, 2012 |
Derma Sciences Announces Pricing of Underwritten Registered Direct Offering of Common Stock Exhibit 99.1 Derma Sciences Announces Pricing of Underwritten Registered Direct Offering of Common Stock PRINCETON, N.J. (April 2, 2012) – Derma Sciences, Inc. (the “Company”)(Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of an underwritten registered direct offering of 2,125,000 shares of common stock at a price of $9.25 per |
|
| April 4, 2012 |
2,125,000 Shares DERMA SCIENCES, INC. Common Stock PURCHASE AGREEMENT Exhibit 1.1 EXECUTION COPY 2,125,000 Shares DERMA SCIENCES, INC. Common Stock PURCHASE AGREEMENT April 2, 2012 Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Derma Sciences, Inc., a Pennsylvania corporation (the “Company”), proposes to sell to you as underwriter (the “Underwriter”), an aggregate of 2,125,000 shares (the “Securities”) of |
|
| April 3, 2012 |
Filed pursuant to Rule 424(b)(5) Registration No. 333-173870 PROSPECTUS SUPPLEMENT (To Prospectus dated May 20, 2011) Derma Sciences, Inc. 2,125,000 Shares of Common Stock We are offering 2,125,000 shares of our common stock. Our common stock is listed on the NASDAQ Capital Market under the symbol “DSCI.” As of March 30, 2012, the closing price for the common stock as reported by the NASDAQ Capita |
|
| April 2, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2011 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-31070 DERMA SCIE |
|
| March 30, 2012 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER By and Among Derma Sciences, Inc., ME Merger Sub Inc., MedEfficiency, Inc., And MedE SR LLC March 27, 2012 TABLE OF CONTENTS Page Article I The Merger 1 1.1 The Merger 1 1.2 Closing; Effective Time 1 1.3 Effect of the Merger 2 1.4 Certificate of Incorporation; Bylaws 2 1.5 Directors and Officers 2 Article II Conversion of Capital Stock; Merger Consideration |
|
| March 30, 2012 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits - FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) F |
|
| March 30, 2012 |
EX-99.1 3 v307962ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Derma Sciences to Acquire MedEfficiency; Expands Proprietary Advanced Wound Care Product Offering with High-Growth, Market-Leading, Gold-Standard Treatment for Diabetic Foot Ulcers PRINCETON, N.J. (March 29, 2012) – Derma Sciences, Inc. (Nasdaq: DSCI)(“Derma Sciences”), a medical device and pharmaceutical company focused on advanced wound care, |
|
| March 28, 2012 |
Subsidiaries of Derma Sciences, Inc. Exhibit 21.1 Subsidiaries of Derma Sciences, Inc. Legal Name Trade Name State/Province of Incorporation Derma First Aid Products, Inc. Derma First Aid Products, Inc. Pennsylvania, United States Derma Sciences Canada Inc. Derma Sciences Canada Inc. Ontario, Canada Sunshine Products, Inc. Sunshine Products, Inc. Missouri, United States Derma Sciences Europe, Ltd. Derma Sciences Europe, Ltd. England, |
|
| March 28, 2012 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2011 ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to Commission file number: 1-31070 DERMA SCIENCES, INC. (Name of |
|
| March 16, 2012 |
EX-99.2 3 ex992to13da207738013031512.htm JOINT FILING AGREEMENT Exhibit 99.2 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, par value $0.01 per share, of De |
|
| March 16, 2012 |
[DERMA SCIENCES, INC. LETTERHEAD] Exhibit 99.1 [DERMA SCIENCES, INC. LETTERHEAD] March 15, 2012 Raging Capital Fund, LP 10 Princeton Avenue Rocky Hill, NJ 08553 Dear Mr. Martin: We are in receipt of your letter dated March 2, 2012 (the “Nomination Letter”), which served to notify Derma Sciences, Inc. (the “Company”) of the nomination by Raging Capital Fund, LP (“Raging Capital”) of two nominees, Paul M. Gilbert and William C. Mart |
|
| March 16, 2012 |
Financial Statements and Exhibits, Other Events - FORM 8-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 13, 2012 Derma Sciences, Inc. (Exact name of registrant as specified in its charter) Pennsylvania 1-31070 23-2328753 (State or other jurisdiction (Commission (IRS employer of incorporation) F |
